BR0111852A - Nova interferona para o tratamento de esclerose múltipla - Google Patents

Nova interferona para o tratamento de esclerose múltipla

Info

Publication number
BR0111852A
BR0111852A BR0111852-8A BR0111852A BR0111852A BR 0111852 A BR0111852 A BR 0111852A BR 0111852 A BR0111852 A BR 0111852A BR 0111852 A BR0111852 A BR 0111852A
Authority
BR
Brazil
Prior art keywords
multiple sclerosis
treatment
ifn
humans
biologically active
Prior art date
Application number
BR0111852-8A
Other languages
English (en)
Inventor
Edward M Croze
Daryl Faulds
T Charis Wagner
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of BR0111852A publication Critical patent/BR0111852A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"NOVA INTERFERONA PARA O TRATAMENTO DE ESCLEROSE MúLTIPLA". A presente invenção se refere a novos ácidos nucléicos e seq³ências de polipeptídeos, que codificam uma interferona-beta-2 ("IFN-<225>2"). Uma composição farmacêutica, que compreende um excipiente farmaceuticamente aceitável e uma proporção terapeuticamente eficiente de um polipeptídeo de IFN-<225>2, um de seus fragmentos biologicamente ativos, ou um de seus derivados biologicamente ativos, é útil no tratamento da esclerose múltipla em seres humanos.
BR0111852-8A 2000-06-16 2001-06-18 Nova interferona para o tratamento de esclerose múltipla BR0111852A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21204600P 2000-06-16 2000-06-16
US09/881,050 US20020025304A1 (en) 2000-06-16 2001-06-15 Novel interferon for the treatment of multiple sclerosis
PCT/US2001/041022 WO2001095929A2 (en) 2000-06-16 2001-06-18 Interferon for treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
BR0111852A true BR0111852A (pt) 2003-05-20

Family

ID=26906704

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0111852-8A BR0111852A (pt) 2000-06-16 2001-06-18 Nova interferona para o tratamento de esclerose múltipla

Country Status (22)

Country Link
US (1) US20020025304A1 (pt)
EP (1) EP1289541A2 (pt)
JP (1) JP2004505021A (pt)
KR (1) KR20030009529A (pt)
CN (1) CN1436086A (pt)
AU (1) AU2001267099A1 (pt)
BG (1) BG107370A (pt)
BR (1) BR0111852A (pt)
CA (1) CA2413077A1 (pt)
CZ (1) CZ20024094A3 (pt)
EE (1) EE200200693A (pt)
HU (1) HUP0300787A2 (pt)
IL (1) IL152996A0 (pt)
LT (1) LT2002123A (pt)
MX (1) MXPA02012308A (pt)
NO (1) NO20025964L (pt)
NZ (1) NZ522849A (pt)
PL (1) PL359562A1 (pt)
RU (1) RU2003100517A (pt)
SI (1) SI21080A (pt)
SK (1) SK17612002A3 (pt)
WO (1) WO2001095929A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7314613B2 (en) * 2002-11-18 2008-01-01 Maxygen, Inc. Interferon-alpha polypeptides and conjugates
BR0316324A (pt) * 2002-11-18 2005-09-27 Maxygen Inc Polipeptìdeos e conjugados de interferon-alfa
EP1712992A1 (en) * 2005-04-11 2006-10-18 Sony Ericsson Mobile Communications AB Updating of data instructions
EP2536435B1 (en) * 2010-02-18 2017-11-15 Janssen Biotech, Inc. Monkey homolog of human interferon omega
DK3411398T3 (da) 2016-02-05 2024-06-24 Orionis Biosciences BV Målrettede terapeutiske midler og anvendelse heraf
KR102642385B1 (ko) 2017-02-06 2024-03-04 오리오니스 바이오사이언시스 엔브이 표적화된 키메라 단백질 및 이의 용도
CN110573172A (zh) 2017-02-06 2019-12-13 奥里尼斯生物科学有限公司 靶向的工程化干扰素及其用途
WO2024192373A1 (en) * 2023-03-16 2024-09-19 A-Alpha Bio Interferon alpha-2 variants

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372206B1 (en) * 1989-03-02 2002-04-16 University Of Florida Orally-administered interferon-TAU compositions and methods
AU2470595A (en) * 1994-05-10 1995-11-29 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
CA2311681A1 (en) * 1997-12-08 1999-06-17 Genentech, Inc. Human interferon-epsilon: a type i interferon
EA200001252A1 (ru) * 1998-05-29 2001-06-25 Байоджен, Инк. КОМПОЗИЦИЯ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА-β-1A(IFN-β-1A) ЧЕЛОВЕКА
JP2002526078A (ja) * 1998-09-18 2002-08-20 ザイモジェネティクス，インコーポレイティド インターフェロン−イプシロン
US20030175897A1 (en) * 2000-04-14 2003-09-18 Thayer Edward C. Human interferon, Zinf2

Also Published As

Publication number Publication date
US20020025304A1 (en) 2002-02-28
NO20025964D0 (no) 2002-12-12
WO2001095929A3 (en) 2002-10-10
CN1436086A (zh) 2003-08-13
HUP0300787A2 (hu) 2003-07-28
KR20030009529A (ko) 2003-01-29
MXPA02012308A (es) 2003-04-25
CZ20024094A3 (cs) 2003-05-14
JP2004505021A (ja) 2004-02-19
NO20025964L (no) 2003-02-14
SI21080A (sl) 2003-06-30
AU2001267099A1 (en) 2001-12-24
BG107370A (en) 2003-11-28
CA2413077A1 (en) 2001-12-20
WO2001095929A2 (en) 2001-12-20
EE200200693A (et) 2004-06-15
PL359562A1 (en) 2004-08-23
EP1289541A2 (en) 2003-03-12
RU2003100517A (ru) 2004-06-27
SK17612002A3 (sk) 2003-08-05
NZ522849A (en) 2004-05-28
IL152996A0 (en) 2003-06-24
LT2002123A (en) 2003-06-25

Similar Documents

Publication Publication Date Title
BG101118A (en) Therapeutical compounds
WO1997049373A3 (en) Treatment and prevention of hiv infection by administration of derivatives of human chorionic gonadotropin
HK184896A (en) Pharmaceutical composition comprising loratadine ibuprofen and pseudoephedrine
KR950002785A (ko) 골량을 증가시키기 위한 부갑상선 호르몬 및 랄옥시펜
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
GB9806632D0 (en) Peptide factor
HK1003978A1 (en) Composition for the treatment of schizophrenia
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
BR0116370A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento de uma doença ou condição mediada por hppar em um paciente.
DE58901401D1 (de) Pharmazeutische zubereitung zur behandlung des diabetes mellitus.
BR9909958A (pt) Formulação farmacêutica, respectivos processo de preparação e uso e método de tratamento ou prevenção de distúrbios ósseos
BR0111852A (pt) Nova interferona para o tratamento de esclerose múltipla
DE69429365D1 (de) Entzündungshemmende zusammensetzung und methode, in welchen des-tyr dynorphin und analoge benutzt werden
BR0201524A (pt) Tratamento de combinação para ansiedade e depressão
CA2334941A1 (en) Tnf-derived peptides for use in treating oedema
KR970703353A (ko) 단핵구 주화성 단백질-4(monocyte chemotactic protein-4)
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
DE69334068D1 (de) Kontrolle der wundvernarbung mit calmodulin-inhibitoren oder protein-kinase-c-inhibitoren
AU8806798A (en) Diphosphonic acid salts for the treatment of osteoporosis
BR0212249A (pt) Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto
AU8019898A (en) Somatostatin and somatostatin agonists for treating insulin insensitivity and syndrome
KR950013519A (ko) 골절 예방 및 치료용 약제
ID24561A (id) Pemakaian protein matriks oligomerik kartilaj untuk mengobati artritis rematoid
AR007059A1 (es) Uso de interferon en la preparacion de medicamentos y composiciones via oromucosal o por contacto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]